Improving antibiotic dosing in special situations in the ICU: Burns, renal replacement therapy and extracorporeal membrane oxygenation

Current Opinion in Critical Care

Volumn 18, Issue 5, 2012, Pages 460-471

  Jamal, Janattul Ain ^a   Economou, Caleb J P ^a   Lipman, Jeffrey ^a,b   Roberts, Jason A ^a,b,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Department of Intensive Care Medicine ^*  (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Critical care; Extracorporeal membrane oxygenation; Pharmacokinetics; Renal replacement therapy; Sustained low efficiency dialysis

Indexed keywords

AMIKACIN; ANIDULAFUNGIN; CARBAPENEM DERIVATIVE; CEFALOTIN; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; DAPTOMYCIN; DORIPENEM; ERTAPENEM; FLUCONAZOLE; GENTAMICIN; LEVOFLOXACIN; LINEZOLID; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; TEICOPLANIN; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; BURN; CONTINUOUS RENAL REPLACEMENT THERAPY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; EXTRACORPOREAL OXYGENATION; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; REVIEW; SINGLE DRUG DOSE; SYSTEMATIC REVIEW;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; BURNS; CRITICAL ILLNESS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTRACORPOREAL MEMBRANE OXYGENATION; GLYCOPROTEINS; HUMANS; INTENSIVE CARE UNITS; RENAL REPLACEMENT THERAPY;

EID: 84865995981     PISSN: 10705295     EISSN: 15317072     Source Type: Journal    
DOI: 10.1097/MCC.0b013e32835685ad     Document Type: Review

References (74)

1. Vincent J-L, Rello J, Marshall J, et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 302:2323-2329.
2. Roberts JA. Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotech 2011; 12:2070-2079.
3. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45:755-773.
4. Hosein S, Udy AA, Lipman J. Physiological changes in the critically ill patient with sepsis. Curr Pharm Biotech 2011; 12:1991-1995.
5. Shekar K, Fraser J, Smith M, Roberts J. Pharmacokinetic changes in patients receiving extracorporeal membrane oxygenation. J Crit Care (in press).
6. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif 2010; 30:195-212.
7. Bogard KN, Peterson NT, Plumb TJ, et al. Antibiotic dosing during sustained low-efficiency dialysis, special considerations in adult critically ill patients. Crit Care Med 2011; 39:560-570.
8. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-1596. (Pubitemid 43810035)
9. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31:345-351.
10. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007; 51:1725-1730. (Pubitemid 46744151)
11. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840-851.
12. Varghese JM, Roberts JA, Lipman J. Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin 2011; 27:19-34.
13. Moore R, Lietman P, Smith C. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155:93-99. (Pubitemid 17225088)
14. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1-10.
15. Safdar N, Andes D, Craig W. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63-68. (Pubitemid 38040177)
16. Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003; 17:479-501. (Pubitemid 38029149)
17. Andes D, Van Ogtrop M, Peng J, Craig W. In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46:3484-3489. (Pubitemid 35192915)
18. Blaser J, Stone B, Groner M, Zinner S. Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance. Antimicrob Agents Chemother 1987; 31:1054-1060. (Pubitemid 17099578)
19. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37:1073-1081. (Pubitemid 23141323)
20. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009; 49:325-327.
21. Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/ pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother 2010; 54:1117-1124.
22. Vincent J-L. Relevance of albumin in modern critical care medicine. Best Pract Res Clin Anaesthesiol 2009; 23:183-191.
23. Zdolsek HJ, Kagedal B, Lisander B, Hahn RG. Glomerular filtration rate is increased in burn patients. Burns 2010; 36:1271-1276.
24. Blanchet B, Jullien V, Vinsonneau C, Tod M. Influence of burns on pharmacokinetics and pharmacodynamics of drugs used in the care of burn patients. Clin Pharmacokinet 2008; 47:635-654.
25. Yang R, Rong X, Hua R, Zhang T. Pharmacokinectics of vancomycin and amikacin in the subeschar tissue fluid in patients with severe burn. Burns 2009; 35:75-79.
26. Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother 2011; 55:4639-4642.
27. Dalley AJ, Deans R, Lipman J, et al. Unbound cephalothin pharmacokinetics in adult burn patients are related to the elapsed time after injury. Antimicrob Agents Chemother 2009; 53:5303-5305.
28. Aoki Y, Urakami T, Magarifuchi H, et al. The importance of pharmacokinetic consultation of cefepime treatment for Pseudomonas aeruginosa bacteremia: a case report of severe thermal burn injury. J Infect Chemother 2011; 17:407-411.
29. Dolton M, Xu H, Cheong E, et al. Vancomycin pharmacokinetics in patients with severe burn injuries. Burns 2010; 36:469-476.
30. Elligsen M, Walker SA, Walker SE, Simor A. Optimizing initial vancomycin dosing in burn patients. Burns 2011; 37:406-414.
31. Lovering AM, Le Floch R, Hovsepian L, et al. Pharmacokinetic evaluation of linezolid in patients with major thermal injuries. J Antimicrob Chemother 2009; 63:553-559.
32. Healy DP, Sombun AD, Gardner JC, et al. Pharmacokinetics of colistin in an adolescent boy with extensive burn injury. J Burn Care Res 2011; 32:e7-e11.
33. Doh K, Woo H, Hur J, et al. Population pharmacokinetics of meropenem in burn patients. J Antimicrob Chemother 2010; 65:2428-2435.
34. Hallam M-J, Allen JM, James SE, et al. Potential subtherapeutic linezolid and meropenem antibiotic concentrations in a patient with severe burns and sepsis. J Burn Care Res 2010; 31:207-209.
35. Patel BM, Paratz J, See NC, et al. Therapeutic drug monitoring of beta-lactam antibiotics in burns patients: a one-year prospective study. Therap Drug Monit 2012; 34:160-164.
36. Roberts JA, Taccone FS, Udy AA, et al. Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother 2011; 55:2704-2709.
37. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007; 46:997-1038. (Pubitemid 350136909)
38. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009; 37:2268-2282.
39. Taccone FS, de Backer D, Laterre P-F, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011; 37:531-535.
40. Seyler L, Cotton F, Taccone FS, et al. Recommended b-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care 2011; 15:R137.
41. Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 2012; 40:1523-1528.
42. Bilgrami I, Roberts JA, Wallis SC, et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother 2010; 54:2974-2978.
43. Hidaka S, Goto K, Hagiwara S, et al. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakugaku Zasshi 2010; 130:87-94.
44. Ohchi Y, Hidaka S, Goto K, et al. Effect of hemopurification rate on doripenem pharmacokinetics in critically ill patients receiving high-flow continuous hemodiafiltration. Yakugaku Zasshi 2011; 131:1395-1399.
45. Chaijamorn W, Jitsurong A, Wiwattanawongsa K, et al. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents 2011; 38:152-156.
46. Bellmann R, Falkensammer G, Seger C, et al. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Int J Clin Pharmacol Ther 2010; 48:243-249.
47. Hayakawa M, Fujita I, Iseki K, Gando S. The administration of ciprofloxacin during continuous renal replacement therapy: pilot study. ASAIO J 2009; 55:243-245.
48. Utrup TR, Mueller EW, Healy DP, et al. High-dose ciprofloxacin for serious gram-negative infection in an obese, critically ill patient receiving continuous venovenous hemodiafiltration. Ann Pharmacother 2010; 44:1660-1664.
49. Spooner AM, Deegan C, D'Arcy DM, et al. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol 2011; 11:11.
50. Vilay AM, Grio M, DePestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39:19-25.
51. Khadzhynov D, Slowinski T, Lieker I, et al. Plasma pharmacokinetics of daptomycin in critically ill patients with renal failure and undergoing CVVHD. Int J Clin Pharmacol Ther 2011; 49:656-665.
52. Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother 2012; 67:977-983.
53. Patel K, Roberts JA, Lipman J, et al. Population pharmacokinetics of fluconazole in critically ill patients receiving continuous venovenous hemodiafiltration: using Monte Carlo simulations to predict doses for specified pharmacodynamic targets. Antimicrob Agents Chemother 2011; 55:5868-5873.
54. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet 2011; 50:99-110.
55. Vance-Bryan K, Guay D, Rotschafer JC. Clinical pharmacokinetics of ciprofloxacin. Clin Pharmacokinet 1990; 19:434-461.
56. Scaglione F, Esposito S, Leone S, et al. Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia. Eur Respir J 2009; 34:394-400.
57. Fliser D, Kielstein J. Extended daily dialysis. In: Jörres A, Ronco C, Kellum J, editors. Management of acute kidney problems. Heidelberg, London, New York and Dordrecht: Springer-Verlag; 2010. pp. 537-545.
58. Kielstein JT, Burkhardt O. Antibiotic dosing in extended dialysis. Clin Infect Dis 2009; 49:1963-1964.
59. Kielstein JT, Burkhardt O. Dosing of antibiotics in critically ill patients undergoing renal replacement therapy. Curr Pharm Biotech 2011; 12:2015-2019.
60. Manley HJ, Bailie GR, McClaran ML, Bender WL. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney Int 2003; 63:1072-1078. (Pubitemid 36315586)
61. Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010; 54:3635-3640.
62. Lorenzen J, Broll M, Kaever V, et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol 2012; 7:385-390.
63. Kielstein JT, Czock D, Schöpke T, et al. Pharmacokinetics and total elimination of meropenem and vancomycin in intensive care unit patients undergoing extended daily dialysis. Crit Care Med 2006; 34:51-56. (Pubitemid 43032379)
64. Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transplant 2009; 24:267-271.
65. Kielstein JT, Eugbers C, Bode-Boeger SM, et al. Dosing of daptomycin in intensive care unit patients with acute kidney injury undergoing extended dialysis: a pharmacokinetic study. Nephrol Dial Transplant 2010; 25:1537-1541.
66. Burkhardt O, Joukhadar C, Traunmüller F, et al. Elimination of daptomycin in a patient with acute renal failure undergoing extended daily dialysis. J Antimicrob Chemother 2008; 61:224-225.
67. Czock D, Hu C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 2006; 1:1263-1268.
68. Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010; 66:291-298.
69. Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med 2004; 32:2437-2442. (Pubitemid 39648225)
70. Burkhardt O, Kaever V, Burhenne H, Kielstein JT. Extended daily dialysis does not affect the pharmacokinetics of anidulafungin. Int J Antimicrob Agents 2009; 34:282-283.
71. Burkhardt O, Thon S, Burhenne J, et al. Sulphobutylether-beta- cyclodextrin accumulation in critically ill patients with acute kidney injury treated with intravenous voriconazole under extended daily dialysis. Int J Antimicrob Agents 2010; 36:93-94.
72. Mehta NM, Halwick DR, Dodson BL, et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 2007; 33:1018-1024. (Pubitemid 46835404)
73. Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009; 63:767-770.
74. Mousavi S, Levcovich B, Mojtahedzadeh M. A systematic review on pharmacokinetic changes in critically ill patients: role of extracorporeal membrane oxygenation. Daru 2011; 19:312-321.